Category: W.L. Gore & Associates
W.L. Gore & Assoc. appeals its $860 million patent infringement loss to C.R. Bard over stent graft technology.
C.R. Bard (NYSE:BCR) had no standing to bring the patent infringement lawsuit that won it a nearly $860 million verdict against W.L. Gore & Assoc., Gore argued in its appeal yesterday.
W.L. Gore touts expanded approval to market its Viabahn endoprosthesis to treat stenosis and thrombosis in synthetic vascular access grafts.
W.L. Gore & Associates today touted expanded FDA approval for its Viabahn endoprosthesis, now indicated for treatment of stenosis and thrombotic occlusions related to synthetic vascular access grafts.
W.L. Gore & Associates lands Japanese approval for its Excluder AAA endoprosthesis with the C3 delivery system.
W.L. Gore & Associates said it won Shonin approval from the Japanese Ministry of Health, Labor & Welfare to market its Excluder AAA endoprosthesis with C3 delivery system for treatment of abdominal aortic aneurysms.
Gore's enrolls the 1st patient in a clinical trial of its Excluder iliac branch devices in treatment of patients with common iliac artery aneurysms.
W.L. Gore & Associates this week enrolled its 1st patient in a study of its Excluder iliac branch devices, evaluating the implants in treatment of common iliac artery aneurysms or aorto-iliac aneurysms.
W.L. Gore & Assoc. says it won CE Mark approval in European Union for the latest iteration of its Excluder stent graft, this time for use in the iliac branch.
W.L. Gore & Assoc. said it won CE Mark approval in the European Union for its Excluder iliac branch stent graft.
Gore said the device is designed to isolate the common iliac artery from systemic blood flow, preserving flow in the external and internal iliac arteries, when used with Excluder AAA endoprosthesis.
W.L. Gore & Assoc. says the FDA granted pre-market approval to its 25cm Viabahn stent graft for peripheral artery disease, claiming the device as the longest available on the U.S. market.
W.L. Gore & Assoc. said it won pre-market approval from the FDA for its 25cm Viabahn endoprosthesis for peripheral arterial disease, claiming the device as the longest stent graft available in the U.S.
Newark, Del.-based Gore said the FDA approved the Viabahn device, which is treated with a heparin bio-active coating, for treating symptomatic PAD in the superficial femoral artery.
W.L. Gore & Assoc. begins the payback of the more than $857 million it owes stent graft rival C.R. Bard for patent infringement with a $36 million royalty check.
W.L. Gore & Associates began paying out the $857.4 million it owes C.R. Bard (NYSE:BCR) for infringing a stent graft patent with a $35.7 million royalty check, according to court documents.